Journal Article

Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population

  • Scobie M
  • Zhou K
  • Ahmed S
  • et al.
JCO Precision Oncology (2023) (7)
DOI: 10.1200/po.23.00176
11Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This real-world analysis of retrospective data from the Veterans Health Affairs examined whether immune checkpoint inhibitor biomarker tumor mutational burden predicts improved overall survival in Veterans with cancer types not included in the KEYNOTE-158 trial.

Cite

CITATION STYLE

APA

Scobie, M. R., Zhou, K. I., Ahmed, S., & Kelley, M. J. (2023). Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population. JCO Precision Oncology, (7). https://doi.org/10.1200/po.23.00176

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free